Building the North Texas Life Science Ecosystem:
One Conversation at a Time
|
One of the defining characteristics of a successful innovation ecosystem is the willingness of leaders, organizations, and companies to come together to share knowledge, build relationships, and advance a region's future.
That spirit was on full display recently as BioNTX was part of welcoming leaders from CRB to Pegasus Park and BioLabs for an inside look at the momentum driving North Texas' growing life science ecosystem. A highlight of the visit was a panel discussion featuring Gina Ford, CEO of BioNTX; Matthew Crommett of Lyda Hill Philanthropies and LH Capital; Kelly Cloud of the Dallas Regional Chamber; and Gabby Everett of BioLabs. Together, they shared perspectives on the unique collaboration that continues to fuel innovation across the region. While each panelist brought a different viewpoint, a common theme emerged: North Texas succeeds because of its collaborative culture. The region's strength is found not only in its institutions and infrastructure, but in the relationships and community leaders who have a shared vision for growth.
The visit also highlighted the important role CRB plays in supporting the life science industry nationwide. As a leader in the design and delivery of advanced life science facilities, CRB has helped create spaces where innovation can thrive—including the laboratories at Pegasus Park and BioLabs that are helping accelerate emerging biotech companies in North Texas.
BioNTX extends its sincere appreciation to CRB for spending time with our community and to Lynne Meers for her leadership, diligence, and continued support in helping showcase the remarkable opportunities emerging throughout North Texas.
|
Second Annual Avantor VWR/BioNTX
Innovation Show Builds Momentum
|
The second annual Avantor VWR/BioNTX Regional Scientific Research Innovation Show at Pegasus Park brought together researchers, entrepreneurs, and industry leaders from across North Texas for an afternoon of discovery, networking, and collaboration.
Attendees explored innovative products and solutions from leading suppliers within the Avantor VWR portfolio while learning about valuable cost-saving opportunities available through BIO Business Solutions and BioNTX membership.
The strong turnout and enthusiastic engagement reflected the continued growth and momentum of the region's life science ecosystem. BioNTX extends its sincere appreciation to Avantor VWR, a valued partner whose ongoing support helps strengthen connections across the community and accelerate innovation throughout North Texas.
Events like this demonstrate that thriving ecosystems are built through strong partnerships, shared knowledge, and a commitment to bringing people together.
|
BIO BREAK: Connect, Collaborate, Innovate
|
BIO BREAK brings the life sciences community together for an evening of connection and conversation. Attendees will have the opportunity to network with peers, share insights on emerging trends, and explore ideas driving collaboration and innovation across the ecosystem. The event is designed to strengthen professional relationships and support a more connected life sciences community in the region.
|
FORT WORTH
October 13, 2026
|
Building the Future of Life Sciences in Fort Worth
July 16, 2026
|
Join the BioNTX Facilities Committee for a dynamic gathering of industry, academic, and facilities leaders exploring the next chapter of life sciences growth in Fort Worth. From recent developments to the realities of building and scaling, this event highlights the collaboration, innovation, and infrastructure driving the region forward.
|
Thank you for your support
|
Join Us This September at the 2026 iC³ Summit
September 24 - 25, 2026
|
The BioNTX iC³ Life Science & Healthcare Innovation Summit is North Texas’s premier convening for the region’s bioscience and healthcare community. Each year, we bring together industry leaders, pioneering researchers, investors, entrepreneurs, and innovators to share insights, explore emerging trends, and collaborate on the next breakthroughs in life sciences and healthcare.
At iC³ 2026, you will have the opportunity to engage with thought leaders, connect with peers, and participate in conversations that are shaping the future of healthcare innovation in North Texas and beyond. Whether you are looking to gain knowledge, showcase your work, or build meaningful partnerships, iC³ provides the platform to make an impact.
Thank you for your support
|
iC³ Hotel Room Block
BioNTX has secured discounted room blocks at nearby hotels for the iC³ Summit,
please feel free to take advantage of these options during your stay.
|
Drury Plaza Hotel Dallas Arlington
101 West Road to Six Flags Street
Arlington TX 76011
|
Live! By Loews
1600 E Randol Mill Road
Arlington, TX 76011
|
How Pegasus Park Is Powering North Texas Biotech Growth
|
In this episode of The DallasMeetup Dime, Gabby Everett of BioLabs at Pegasus Park discusses how Pegasus Park is helping position North Texas as a leading biotech and life sciences hub.
The conversation explores support for early-stage science and healthcare startups, the growth of Dallas’s innovation ecosystem, and how increased collaboration between research, entrepreneurship, and industry is accelerating regional impact.
|
AstraZeneca’s Imfinzi Approved for
High-Risk Early Bladder Cancer in the U.S.
|
AstraZeneca’s Imfinzi (durvalumab) has been approved in the U.S. in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk Non-muscle-invasive bladder cancer (NMIBC). The FDA approval is based on the Phase III POTOMAC trial, which showed the combination reduced the risk of recurrence, progression, or death compared with BCG alone. The therapy represents the first new treatment approach in this setting in more than 30 years.
|
Johnson & Johnson Reports Positive Phase 3 Results for
Apalutamide in High-Risk Prostate Cancer
|
Johnson & Johnson announced positive Phase 3 PROTEUS study results showing that apalutamide with hormone therapy improved outcomes for patients with high-risk localized or locally advanced prostate cancer undergoing surgery. The combination was given before and after prostatectomy and significantly increased the likelihood of minimal or no cancer remaining at surgery, while also reducing the risk of metastasis or death and extending time before additional treatment was needed.
|
Lantern Pharma Shares Updated Phase 2 Data
From HARMONIC Trial in Lung Cancer
|
Lantern Pharma, an AI-driven precision oncology company, reported updated clinical data from its Phase 2 HARMONIC trial evaluating LP-300 in combination with carboplatin and pemetrexed in patients with EGFR L858R-mutant non-small cell lung cancer following TKI therapy. The updated analysis shows a consistent and deepening progression-free survival benefit with longer treatment duration, with the strongest signal in the L858R subgroup, a population with poor prognosis and limited post-TKI options.
|
Nanoscope Therapeutics Partners With McKesson’s InspiroGene
to Support U.S. Launch of MOGENRY™ Gene Therapy
|
Nanoscope Therapeutics announced a U.S. commercialization services agreement with InspiroGene by McKesson to support the planned launch of its retinal gene therapy MOGENRY™, pending regulatory approval. The collaboration will provide specialty pharmacy, distribution, and patient support services to help prepare for U.S. commercialization in retinal degenerative diseases, including retinitis pigmentosa.
|
Secretome Therapeutics Raises $30 Million Series A to
Advance STM-01 for Duchenne Muscular Dystrophy
|
Secretome Therapeutics announced the closing of a $30 million Series A financing led by RA Capital Management to advance its neonatal cardiac progenitor cell–derived therapies, including lead program STM-01 for Duchenne muscular dystrophy–associated cardiomyopathy. The proceeds will support continued development of the program toward later-stage clinical trials in Duchenne muscular dystrophy and related cardiomyopathies.
|
Advanced Technology International Awarded Navy OTA to
Manage LETHALITY AI and Defense Consortium
|
Advanced Technology International has been awarded an Other Transaction Agreement by the Naval Surface Warfare Center Corona Division to serve as consortium manager for the LETHALITY consortium, focused on advancing warfighting capabilities in AI, cyber, data analytics, advanced computing, and related technologies. The consortium will bring together industry, academia, government, and non-traditional defense partners to accelerate development of integrated solutions supporting maritime and surface defense operations.
|
Polsinelli Recognized in IAM Patent 1000 2026 for
Patent Prosecution and Litigation Excellence
|
Polsinelli’s Intellectual Property Department has once again been recognized in IAM Patent 1000 The World’s Leading Patent Professionals 2026 for its strengths in patent prosecution and patent litigation. This marks the firm’s seventh national level ranking, underscoring its continued excellence and consistency in complex intellectual property matters.
|
PSC Biotech Named Exclusive Distributor for
De Lama Sterilization Systems Across Key Global Markets
|
PSC Biotech has been appointed the exclusive distributor and local service provider for De Lama across the United States, Canada, Singapore, and Australia. The partnership expands access to De Lama’s sterilization, washing, and decontamination technologies for life sciences companies, while combining PSC Biotech’s validation and compliance expertise to support implementation and operation within regulated GMP environments.
|
UNT Health Fort Worth Becomes First Texas Site in
National Alzheimer’s Biomarker Study for Down Syndrome
|
UNT Health Fort Worth’s Institute for Translational Research will become the first site in Texas to join the national ABC DS study, a National Institutes of Health funded initiative examining Alzheimer’s disease in adults with Down syndrome. The study will provide no cost brain health evaluations and research participation opportunities for eligible adults age 25 and older, including cognitive assessments, imaging, and medical evaluations. Researchers aim to better understand early biomarkers of Alzheimer’s disease and improve future treatment pathways for this high risk population.
|
UT Arlington Study Links Estrogen Loss to Liver Inflammation
and Increased Heart Disease Risk After Menopause
|
Researchers at the University of Texas at Arlington have identified new mechanisms linking estrogen loss after menopause to increased cardiovascular disease risk, highlighting the liver and immune system as key drivers. The study found that declining estrogen disrupts cholesterol metabolism and increases inflammation, in part through elevated activity of the immune-related enzyme IDO1, leading to impaired cholesterol clearance and systemic inflammatory changes. The findings suggest that hormone linked metabolic and immune pathways could serve as potential targets for future therapies aimed at reducing heart disease risk in postmenopausal women.
|
UT Southwestern Study Reveals Direct DNA Transfer
Between Human Cells That Can Alter Cell Function
|
Scientists at UT Southwestern Medical Center’s Children’s Medical Center Research Institute have discovered that large pieces of DNA can move directly between human cells through nanotubes and remain functional in recipient cells. Published in Cell, the study shows transferred DNA can integrate into the genome, persist through cell division, and alter cell behavior, challenging the long-held view that human cell genomes evolve independently. Researchers say the findings could reshape understanding of cancer development, genome instability, and how cells influence one another.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
Opportunities to Mentor, Teach,
and Inspire Future Biotech Leaders
|
Nucleate Dojo is an undergraduate biotech program launching in September 2026 in partnership with SMU, UTD, and UTSW. The program helps undergrads break into the biotech industry through a faculty and industry seminar series, hands-on skills workshops, and mini-projects built around biotech industry problem statements, culminating in a final competition for cash prizes.
They are looking for professionals to get involved in any of the following roles (feel free to choose more than one):
- Speaker – Lead a topic-specific seminar (~1 hour, plus curriculum prep).
- Facilitator – Lead a hands-on workshop (~1 hour, plus activity prep).
- Mentor – Join project work time during workshops (1 hour/workshop, ~9 hours total) and stay accessible to student teams between sessions for questions and guidance.
This is a great way to support the next generation of biotech talent in Dallas. Programming will take place at the aforementioned institutions. Participation is in your own individual capacity.
|
Upcoming Events & Opportunities
|
BIO BREAK Dallas
Join BioNTX, Deloitte, and Griffith Barbee for the BIO BREAK Dallas to build meaningful connections with the North Texas life science industry.
June 11th | Dallas, TX
|
Future of San Antonio Healthcare & Life Sciences
Join Bisnow for a focused look at the San Antonio Healthcare & Life Sciences market and the strategies defining its next phase of growth.
June 16th | San Antonio, TX
|
2026 National Meeting
Join NIIMBL to connect with leaders shaping the future of manufacturing and advancing innovation, workforce development, and national health security.
June 23rd - 25th | Washington, DC
|
Taco 'Bout BioTech Breakfast @ BIO Convention
Come meet the BioTexas delegation for a casual breakfast on your way to the BIO Convention Center.
June 24th | San Diego, CA
|
TechFW Q2 Tech Together Happy Hour
Join TechFW for their Q2 TechTogether event to connect with fellow entrepreneurs, innovators, and ecosystem supporters over drinks and snacks.
June 24th | Fort Worth, TX
|
Join Women in Bio for a summer drop-in mixer to connect with fellow chapter members and expand your network, exchange insights, and unwind over great conversation as we kick off the summer season together.
June 25th | Plano, TX
|
National Chronic Disease Day
Luncheon Symposium at MassBio
Join Good Days to explore federal initiatives and partnerships advancing patient care, and connect on keeping patient voices central to innovation and policy.
July 10th | Cambridge, MA
|
Presents
Partners in Progress: Fort Worth Biotech
Join the BioNTX Facilities Committee for a gathering of industry, academic, and facilities leaders focused on the collaboration and infrastructure driving Fort Worth’s life sciences growth and development.
July 16th | Fort Worth, TX
|
Thank you for your support!
|
|
